PRENATAL OPIOID EXPOSURE NOT TIED TO NEUROPSYCHIATRIC DISORDERS IN OFFSPRING

(HealthDay News) — Prenatal opioid exposure seems not to be associated with a meaningful increase in the risk for neuropsychiatric disorders in offspring, according to a study published online April 24 in The BMJ.

Jiseung Kang, Ph.D., from the University of Oxford in the United Kingdom, and colleagues conducted a nationwide birth cohort study to examine the potential association between prenatal opioid exposure and the risk for neuropsychiatric disorders in children in South Korea. Data were included for 3,128,571 infants, from 2,299,664 mothers; 2,912,559 infants had no prenatal opioid exposure and 216,012 had prenatal opioid exposure. Three cohorts were formed: full unmatched, propensity score-matched, and child screening cohorts, all of which were paired with sibling comparison cohorts.

The researchers found that in children with prenatal opioid exposure, the fully adjusted hazard ratio for neuropsychiatric disorders was 1.07 in the matched cohort, but no significant association was seen in the sibling comparison cohort. Increased risks for neuropsychiatric disorders in children were seen in association with prenatal opioid exposure during the first trimester, higher opioid doses, and long-term opioid use of 60 days or more (hazard ratios, 1.11, 1.15, and 1.95, respectively). A modestly increased risk for severe neuropsychiatric disorders (hazard ratio, 1.30), mood disorders, attention-deficit/hyperactivity disorder, and intellectual disability in the child were seen with prenatal opioid exposure.

“Although a slightly increased risk was observed for neuropsychiatric disorders, given the observational nature of the study, these results should not be considered clinically meaningful,” the authors write.
One author disclosed ties to the pharmaceutical industry.

Source: MSD Manuals

About STELLAPHARM

Stellapharm is one of leading generics pharmaceutical companies and strong producer of anti-viral drugs in Vietnam. The company established in Vietnam in 2000; and focuses on both prescription drugs and non-prescription especially in cardiovascular diseases, antiviral drugs, anti-diabetics drugs, etc. and our products are now used by millions of patients in more than 50 countries worldwide.

The company is globally recognized for its quality through our facilities have been audited and approved by stringent authority like EMA, PMDA, Taiwan GMP, local WHO and others.

Additional information for this article: Stellapharm J.V. Co., Ltd. – Branch 1
A: 40 Tu Do Avenue, Vietnam – Singapore Industrial Park, An Phu Ward, Thuan An City, Binh Duong Province, Vietnam
T: +84 274 376 7470 | F: +84 274 376 7469 | E: info@stellapharm.com | W: www.stellapharm.com